Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 6, 2011

Investigators Identify Prognostic Marker for Treating Hep C with Peg-Interferon and Ribavirin

  • Plasma levels of the protein IP-10 predict , prior to therapy initiation, the efficacy of treating chronic hepatitis C infection with pegylated-interferon and ribavirin, according to scientists at Inserm and Institut Pasteur. They say that they have developed a prognostic test for hepatitis C based on these results and anticipate commercialization this year.

    The study, published in the Journal of Clinical Investigation, was conducted in the research lab of Matthew Albert, Ph.D. Dr. Albert’s team found IP-10 elevated in those patients for whom treatment was ineffective. This observation was paradoxical as IP-10 is considered a pro-inflammatory molecule, which should have facilitated migration of activated T cells to the liver, the exact cell types responsible for viral immunity.

    The researchers figured out that IP-10 had been catabolized and a truncated form was present in the HCV patients. This means that the short form of the protein acts as an antagonist and inhibits T-cell recruitment. The investigators thus suggest that the antagonist form of IP-10 is responsible for treatment failures in 50% of patients.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »